Eli Lilly To Buy Back Cymbalta Rights For $400M
Lilly will also pay Boehringer royalties on sales through 2012, the company said in an announcement.
The companies have marketed Cymbalta outside the U.S. and Japan for several years.
Lilly has exclusive rights to Cymbalta in the U.S. and partners with Shionogi & Co. Ltd. in Japan on developing and...
To view the full article, register now.